Sriram Iyer, Chief Executive Officer of Apollo Health & Lifestyle, is recognised for his leadership in building patient-centric healthcare platforms, spanning diagnostics and specialised care, aligned with the Apollo Hospitals Group’s long-standing healthcare mission.
Apollo Hospitals Group, founded over four decades ago, continues to be driven by a strong purpose of impacting a billion lives through clinical excellence delivered with empathy and care. Apollo Health & Lifestyle operates as an integral part of this ecosystem, guided closely by the Group’s leadership and long-term healthcare mission.
Apollo Health & Lifestyle manages multiple healthcare formats, with a strong presence in primary care through Apollo Clinics, Apollo Sugar, Apollo Dental, and Apollo Diagnostics. In addition, the organisation operates focused single-specialty formats across mother and childcare, fertility services, ambulatory care, and dialysis. These segments, according to Mr. Iyer, require deeper focus, wider market presence, and sustained investment to address evolving patient needs and systemic gaps.
Mr. Iyer emphasised that diagnostics play a foundational role in healthcare delivery, particularly as the first step in disease detection. While hospital infrastructure in India has expanded rapidly across metros and state capitals, diagnostics remains the most scalable healthcare service capable of reaching remote and underserved regions. Early testing and early detection, he noted, are essential responsibilities for the diagnostics industry as a whole.
Despite growing healthcare demand beyond major cities, significant unmet needs persist in towns with populations below one million. These regions are often served either by government facilities or by local laboratories that may operate at lower price points but do not always adhere to stringent quality standards such as NABL accreditation. This creates challenges for organised diagnostics providers seeking to balance quality, affordability, and expansion.
Apollo Diagnostics is addressing this gap through a structured expansion strategy. The company plans to reach approximately 1,000 towns over the next three years and has committed to adding a consistent number of new laboratories annually, building on the addition of 25 labs in the previous year. Quality remains central to this expansion, with regional reference laboratories accredited by NABL and select facilities holding CAP accreditation, one of the highest global standards in laboratory quality.
The diagnostics portfolio spans both acute illnesses testing and chronic and wellness-driven assessments. Apollo Diagnostics is increasingly aligning its services with a broader shift in healthcare—from preventive to predictive and personalised care. Leveraging patient demographics, clinical data, and emerging technologies, Mr. Iyer said the organisation aims to identify health risks earlier and support targeted interventions.
Advanced analytics, artificial intelligence, and genomics are playing a growing role in this transformation. By integrating genomic markers with demographic and clinical data, Apollo Diagnostics is working towards creating more individualised health journeys. The organisation is also exploring pharmacogenomics and polygenic risk scoring as tools to further personalise care and improve treatment outcomes.
Many of these advanced genomic tests are now part of Apollo’s ProHealth platform, its flagship preventive health and check-up offering. With access to large-scale patient data and growing analytical capabilities, Apollo Health & Lifestyle aims to generate insights that support clinicians, improve patient outcomes, and contribute to the broader healthcare ecosystem.
Under Mr. Iyer’s leadership, Apollo Health & Lifestyle is sharpening its focus on diagnostics, technology integration, and specialised care to expand access to early detection and personalised healthcare across India, while balancing scale with clinical quality and long-term health outcomes.
